Morgan Stanley’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-35,366
| Closed | -$30.8K | – | 7765 |
|
|
2023
Q2 | $30.8K | Sell |
35,366
-9,223
| -21% | -$6.58K | ﹤0.01% | 6400 |
|
|
2023
Q1 | $31.2K | Sell |
44,589
-3,192
| -7% | -$2.59K | ﹤0.01% | 6457 |
|
|
2022
Q4 | $39.2K | Sell |
47,781
-30,103
| -39% | -$29.7K | ﹤0.01% | 6394 |
|
|
2022
Q3 | $81K | Sell |
77,884
-16,037
| -17% | -$25.6K | ﹤0.01% | 6185 |
|
|
2022
Q2 | $153K | Sell |
93,921
-704,233
| -88% | -$1.46M | ﹤0.01% | 6022 |
|
|
2022
Q1 | $2.35M | Sell |
798,154
-19,836
| -2% | -$69.5K | ﹤0.01% | 4393 |
|
|
2021
Q4 | $3.91M | Buy |
817,990
+121,147
| +17% | +$782K | ﹤0.01% | 3974 |
|
|
2021
Q3 | $5.28M | Sell |
696,843
-36,452
| -5% | -$233K | ﹤0.01% | 3628 |
|
|
2021
Q2 | $5.47M | Buy |
733,295
+525,356
| +253% | +$4.05M | ﹤0.01% | 3683 |
|
|
2021
Q1 | $1.62M | Sell |
207,939
-865,190
| -81% | -$8.65M | ﹤0.01% | 4420 |
|
|
2020
Q4 | $9.92M | Buy |
1,073,129
+986,495
| +1,139% | +$8.57M | ﹤0.01% | 2513 |
|
|
2020
Q3 | $598K | Buy |
86,634
+71,034
| +455% | +$431K | ﹤0.01% | 4552 |
|
|
2020
Q2 | $103K | Buy |
15,600
+4,228
| +37% | +$15.3K | ﹤0.01% | 5388 |
|
|
2020
Q1 | $21K | Sell |
11,372
-3,094
| -21% | -$8.16K | ﹤0.01% | 5803 |
|
|
2019
Q4 | $27K | Sell |
14,466
-918
| -6% | -$1.53K | ﹤0.01% | 6034 |
|
|
2019
Q3 | $22K | Sell |
15,384
-7,367
| -32% | -$16.1K | ﹤0.01% | 5976 |
|
|
2019
Q2 | $64K | Buy |
22,751
+20,970
| +1,177% | +$83.5K | ﹤0.01% | 5508 |
|
|
2019
Q1 | $8K | Sell |
1,781
-61,733
| -97% | -$304K | ﹤0.01% | 6245 |
|
|
2018
Q4 | $270K | Buy |
63,514
+49,627
| +357% | +$383K | ﹤0.01% | 5157 |
|
|
2018
Q3 | $152K | Sell |
13,887
-1,631
| -11% | -$19.1K | ﹤0.01% | 5558 |
|
|
2018
Q2 | $253K | Buy |
+15,518
| New | +$225K | ﹤0.01% | 5453 |
|
Morgan Stanley's SURF Position: Q3 2023 in Review
Morgan Stanley sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 35,366 shares — an estimated $30.8K sold.
Morgan Stanley first reported a position in SURF in Q2 2018 and held it in 21 quarters. The position peaked at $9.92M in Q4 2020. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Morgan Stanley reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 35,366 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $30.8K.
- Morgan Stanley first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 21 quarters.
- Morgan Stanley's Surface Oncology, Inc. Common Stock position peaked at $9.92M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.